Stephen Chanock Elected to the National Academy of Medicine
Stephen Chanock, director of DCEG, was elected as a member of the National Academy of Medicine on October 21, 2024 during their annual meeting.
Stephen Chanock, director of DCEG, was elected as a member of the National Academy of Medicine on October 21, 2024 during their annual meeting.
China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.
Anticoagulants have long been fundamental in preventing and treating thromboembolic disorders, with a recent shift of focus towards direct oral anticoagulants, thanks to their ease…
In this discussion, Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, is joined by Sanam Loghavi, MD, The University of Texas MD…
Join us at our annual in-person conference to hear expert speakers on LGBTIQ+ cancer care and make amazing networking connections!
Trial of tucatinib and trastuzumab also showed benefits for HER2-mutated breast cancer: Thursday 24 October 2024, Barcelona, Spain: Drugs designed to target HER2-postive breast cancer…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Dissection of genotype–phenotype relationships in hemophilia B (HB) is particularly relevant for challenging (mild HB) or for HB-associated but unclassified factor (F)IX missense variants.